Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi GMP Problems Require Top-level Sit-down With FDA, But Product Impact Limited So Far

Executive Summary

Agency’s warning letter also includes an uncommon request for a “global assessment” of operations. FDA says sterility of TheraCys lots manufactured since 2000 cannot be assured; company has halted manufacture of the bladder cancer drug and set limits on orders of its Pentacel vaccine.

You may also be interested in...



A Closer Look: Is Double-Digit Growth Sustainable In Emerging Markets? (Part 1 of 2)

A new debate among investors concerns whether double-digit growth is possible across emerging markets or only in China. PharmAsia News takes a closer look.

Sandoz GMP Warning Letter: Is The Problem Documentation, Or Leadership?

Upper management at Novartis and Sandoz are responsible for repeated cGMP violations at three Sandoz plants, FDA suggests. The agency’s warning letter, aimed at three sites in North Amercia, includes what may become new biolerplate instructions on drug shortages.

Sanofi Lacks System To Prevent Microbial Contamination At Its German Plant, FDA Says

Sanofi-Aventis has not established or followed appropriate written procedures to prevent microbiological contamination of drug products at its manufacturing facility in Frankfurt, FDA told the company.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel